Skip to main content
  • Oral PCSK9 Inhibitor MK-0616 Significantly Reduces LDL-C vs. Placebo at 8 Weeks: Randomized Trial

    Using varying dosage levels, the oral PCSK9 inhibitor MK-0616 significantly and clinically reduced low-density lipoprotein cholesterol (LDL-C) in patients with hypercholesterolemia and a wide range of atherosclerotic cardiovascular disease (ASCVD) risk and background statin therapy compared to placebo after 8 weeks, new randomized trial results show.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details